The Lynx Group
Cholangiocarcinoma News

Emerging Molecular Targets in Cholangiocarcinoma: IDH1, HER2, BRAF, and Beyond

December 2020, Vol 1, No 3

Targeted therapy has improved survival for patients with cancer across a broad spectrum of disease sites, but until recently, progress has been slow in the treatment of patients with cholangiocarcinoma (CCA).

At the 2020 Annual Cholangiocarcinoma Summit, Imane El Dika, MD, Assistant Attending Physician, Gastrointestinal Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, discussed new data regarding targeting IDH1, HER2, BRAF, and other mutations as potential targets in the treatment of patients with CCA.

IDH1 Mutations

Although their prognostic role in CCA remains unclear, IDH1 mutations are reported in up to 25% of patients with CCA.

In the phase 3 clinical trial of patients with chemotherapy-refractory CCA and IDH1 mutation, the first-in-class ivosidenib (Tibsovo), an oral IDH1 inhibitor, increased progression-free survival (PFS) and overall survival by more than 1 month compared with placebo.

Other clinical trials targeting CCA and IDH mutation are focused on the evaluation of combination therapies. A new phase 2 clinical trial of ceralasertib, an ataxia telangiectasia and rad3–related kinase inhibitor, and olaparib (Lynparza), a PARP inhibitor, is currently enrolling patients. Investigators are also exploring the combination of PARP inhibition and immunotherapy, Dr El Dika said.

HER2 Mutations

Another potential molecular target is the HER2 mutation seen in several cancers.

HER2 mutations are more common in gallbladder cancer, but have been reported in 0.9% to 4.7% of patients with CCA,” said Dr El Dika.

Initial reports from the phase 2 MyPathway clinical trial showed an objective response rate (ORR) of 37.5% and a median PFS of 4.2 months among 11 pretreated patients who received the combination of pertuzumab (Perjeta) and trastuzumab (Herceptin).

A basket clinical trial of trastuzumab deruxtecan (Enhertu), a HER2-targeted antibody–drug conjugate, also reported 1 response among 6 patients with biliary tract cancers.

Neratinib (Nerlynx), a tyrosine kinase inhibitor of HER2 approved for the treatment of patients with HER2-positive breast cancer, yielded an ORR of 10% in a phase 2 basket study of patients with CCA, gallbladder cancer, or biliary cancer and HER2 mutation. The responses were primarily seen in patients with gallbladder cancer or with CCA, said Dr El Dika.

Zanidatamab, a bispecific antibody, is another targeted agent under investigation. An ORR of 67% with this drug in an early-phase clinical trial of heavily pretreated patients led to an ongoing phase 2 study.

“Zanidatamab was also well-tolerated, with no grade 3 side effects,” said Dr El Dika.

BRAF Mutations and Beyond

Although uncommon in biliary cancers, BRAF mutation is also being studied with interesting results, noted Dr El Dika. A study of 43 patients with CCA and BRAF V600E mutation who received the BRAF inhibitor dabrafenib (Tafinlar), and the MEK inhibitor trametinib (Mekinist), had an ORR of 51%, a median PFS of 9.1 months, and an overall survival of 13.5 months.

BRCA and HRD mutations have been identified in 3.6% of biliary cancers. “HRD mutations are potentially more common in extrahepatic and gallbladder cancer, but have been reported in intrahepatic CCA as well,” said Dr El Dika. “They also carry a potentially favorable prognosis,” she added.

In addition to patients with BRCA1 or BRCA2 mutations, those with ATM, CHEK2, PALB2, PTEN, and NBM mutations have had favorable responses to platinum therapy, Dr El Dika explained.

Immunotherapy Shows Mixed Results

PD-L1 overexpression has been reported in 8.6% of patients with CCA, who may therefore benefit from immunotherapy, Dr El Dika said. So far, however, immunotherapy has had mixed results in the treatment of biliary tract cancers.

In patients with CCA and PD-L1 expression, the phase 1 KEYNOTE-028 study of pembrolizumab (Keytruda) showed a response rate of 17.4% but the phase 2 KEYNOTE-158 only had 5.8% responses.

By contrast, early data reported at the 2020 ASCO meeting showed that the combination chemotherapy of gemcitabine and cisplatin plus immune checkpoint blockade with durvalumab (Imfinzi) and tremelimumab had a median PFS of 13 months, an overall survival of 15 months, and a response rate of 50% to 73%.

“The response rate is strikingly high, and the disease control rate and duration of response are much higher than the historical data,” said Dr El Dika. “However, more mature data and more information about the study population are still needed.”

In the meantime, clinicians should consider routine molecular testing in all patients with CCA, Dr El Dika concluded.

Related Items

Accelerated Approval Granted for Infigratinib for the Treatment of Metastatic Cholangiocarcinoma
Web Exclusives
Infigratinib has been approved to treat adults with previously treated locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 fusion or other rearrangement.
The Latest Research in Biliary Tract Cancers Presented at ASCO GI 2021
March 2021, Vol 2, No 1
At the CCA Summit held during the 2021 ASCO Gastrointestinal (GI) Cancers Symposium, Rachna T. Shroff, MD, MS, Chief, Section of GI Medical Oncology, University of Arizona Cancer Center, Tucson, discussed 15 clinical trials that were presented at the ASCO GI Cancers Symposium on cholangiocarcinoma (CCA) and hepatobiliary diseases. She highlighted key advances related to chemotherapy, targeted therapies, and biomarkers in the management of biliary tract cancers, including CCA.
What’s Next in Immunotherapy in Biliary Tract Cancers?
March 2021, Vol 2, No 1
The rationale for immunotherapy in biliary tract cancers is strong, because these cancers are inflammatory in nature, according to Abby Siegel, MD, MS, Executive Director and PDT Lead, Hepatobiliary Oncology, Global Clinical Development at Merck. Inroads are being made into biomarkers predictive of response to immunotherapy in biliary cancers, Dr Siegel said at the 2020 Annual Cholangiocarcinoma Summit.
Periadjuvant Approaches to Biliary Tract Cancers Offer Hope for Improved Outcomes
March 2021, Vol 2, No 1
A periadjuvant, or perioperative, approach to the treatment of biliary tract cancers, including cholangiocarcinoma (CCA), has several potential advantages that may offer an opportunity to improve outcomes in these diseases, said James Harding, MD, Regional Director, Early Drug Development, Memorial Sloan Kettering Cancer Center, New York, NY, at the 2020 Annual Cholangiocarcinoma Summit.
The Updated Staging System for Cholangiocarcinoma: Implications for Hilar and Intrahepatic Disease
March 2021, Vol 2, No 1
Flavio Rocha, MD, Hepatopancreatobiliary Surgeon, Virginia Mason Medical Center, Director of Research, Digestive Disease Institute, and Associate Medical Director of the Floyd and Delores Jones Cancer Institute, Seattle, WA, provided an overview of the changes made in the 8th edition of the AJCC’s tumor, node, metastasis (TNM) staging system at the 2020 Annual Cholangiocarcinoma Summit. These changes have direct implications for the management of patients with hilar or intrahepatic CCA.
Targeted Therapies in Cholangiocarcinoma: Next-Generation Sequencing Is a Must
December 2020, Vol 1, No 3
The recent FDA approval of the first FGFR inhibitor, pemigatinib (Pemazyre), and the positive results from the phase 3 study of the first IDH1 inhibitor, ivosidenib (Tibsovo), represent major breakthroughs in the treatment of patients with cholangiocarcinoma (CCA), a rare cancer associated with poor outcomes. However, the duration of response with these agents is still relatively short.
Gallbladder Cancer: Novel Approaches to Therapy Are Needed
December 2020, Vol 1, No 3
The current standard of care for the systemic treatment of patients with advanced gallbladder cancer is the chemotherapy combination of gemcitabine and cisplatin, which is suboptimal, yielding only modest benefit, said Richard Kim, MD, Section Chief, Gastrointestinal Medical Oncology, Moffitt Cancer Center, Tampa, FL, at the 2020 Cholangiocarcinoma Summit.
FGFR Inhibition in Cholangiocarcinoma: Overcoming Acquired Resistance
December 2020, Vol 1, No 3
In April 2020, the FDA granted accelerated approval to pemigatinib (Pemazyre), the first targeted therapy for cholangiocarcinoma (CCA). The FGFR inhibitor was approved for adults with CCA and FGFR2 fusion.
Improving Chemotherapy Combinations and Novel Treatments Are Needed in Advanced Biliary Tract Cancer
December 2020, Vol 1, No 3
New cytotoxic chemotherapy regimens and novel combinations are being evaluated in clinical trials in an effort to improve the outcomes of chemotherapy in the adjuvant and palliative settings in patients with biliary tract cancer, including cholangiocarcinoma (CCA), said Angela Lamarca, MD, PhD, MSc, Consultant, Medical Oncology, the Christie NHS Foundation Trust, Manchester, United Kingdom. She discussed the future of cytotoxic chemotherapy for this patient population at the 2020 Cholangiocarcinoma Summit.
Role of Liver Transplant in Patients with Cholangiocarcinoma
December 2020, Vol 1, No 3
Liver transplant is emerging as a treatment option in patients with unresectable hilar or intrahepatic cholangiocarcinoma (CCA), with accumulating data supporting transplant protocols in patients with early-stage CCA.

Subscribe to CCA News

Stay up to date with personalized medicine by subscribing to recieve the free CCA News print publication or weekly e‑Newsletter.

I'd like to recieve: